Navigation Links
The Continued Uptake of Key Agents Such as Januvia, Bydureon and Byetta Will Drive The Type 2 Diabetes Drug Market to Nearly Double From $19 Billion in 2009 to $36 Billion in 2019
Date:9/21/2010

BURLINGTON, Mass., Sept. 21 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the continued uptake of key agents such as Merck's Januvia, Eli Lilly/Amylin/Alkermes' Bydureon and Amylin/Eli Lilly's Byetta will drive the type 2 diabetes drug market to nearly double from $19 billion in 2009 to $36 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

The Pharmacor 2010 findings from the topic entitled Type 2 Diabetes reveal that agents from the incretin mimetics drug class—dipeptidyl peptidase-IV (DPP-IV) inhibitors and glucagon-like peptide-1 (GLP-1) analogues—are the most promising drug classes because they improve upon key areas of safety and efficacy. DPP-IV inhibitors such as Januvia have a very low risk of hypoglycemia and an excellent tolerability profile, making them suitable for widespread use. GLP-1 analogues such as Bydureon and Byetta combine superior glucose-lowering and weight-loss capabilities and are particularly useful for the significant proportion of type 2 diabetics who are obese. Among all drug classes, DPP-IV inhibitors and GLP-1 analogues will experience the largest upturn in market share, increasing from 12 percent in 2009 to 30 percent in 2019.

"Januvia dominates the DPP-IV inhibitor class and will consolidate its leading position while other DPP-IV inhibitors will struggle, owing to their lack of clinical advantages over Januvia," said Decision Resources Analyst Yannick Maneuf, Ph.D. "GLP-1 analogues have a strong efficacy profile, they elicit weight loss and also have limited safety liabilities and—despite requiring an injection—GLP-1 analogues enjoy great popularity among thought leaders, who see improved glycemia and weight loss in obese type 2 diabetics as landmark progress."

Bydureon, a once-weekly therapy, will earn the most sales in the GLP-1 analo
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. K-V Pharmaceutical Company Receives Notification From New York Stock Exchange of Compliance With Quantitative Continued Listing Standards
2. Interventional Spine®, Inc. Announces Continued Success With Its Unique PERPOS® Percutaneous Cervical System
3. K-V Pharmaceutical Company Notified by New York Stock Exchange of Non-Compliance With Continued Listing Standards
4. Caraco Pharmaceutical Laboratories, Ltd. Receives Notice Regarding NYSE Amex Continued Listing Standards
5. Department of Defense Funding Shows Continued and Bi-Partisan Support for STB® Lifesaving Technologies Products to Stop Blood Loss
6. Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year
7. Abbott Annual Meeting Highlights Continued Strong Performance in 2009; Sustained Growth in 2010
8. Philips Introduces Breakthrough Medical Alert Service That Helps Enable Continued Independence for Seniors by Improving Access to Help in the Event of a Fall
9. NYSE Amex Provides Interleukin Genetics, Inc. Extension To Meet Continued Listing Standards
10. Benefits of CyberKnife Radiosurgery for Lung Cancer Drive Continued Adoption
11. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... -- Pharma Major Lupin Limited anunció ... ZAO "Biocom" en Rusia bajo ciertas condiciones de ... en el mercado farmacéutico de Rusia que registró ... uno de los 10 principales mercados farmacéuticos del ... una década, el mercado farmacéutico ruso registró un ...
(Date:7/2/2015)... and VANCOUVER , July 2, ... (TSX-V: EPI) announced today that its common shares have been ... ("NASDAQ") under the symbol "EPIX". ESSA will begin ... retain its listing on the TSX Venture Exchange under the ... of the common shares on the NASDAQ, each of the ...
(Date:7/2/2015)... LAUDERDALE, Fla. , July 2, 2015 /PRNewswire/ ... Co., is pleased to announce that its Consumer ... ("Insight Beverages") to Kerry Group plc (ISE: KRZ) ... on taste and nutrition systems, as well as ... beverage and pharmaceutical markets. Farlie Turner served as ...
Breaking Medicine Technology:Lupin adquiere Biocom en Rusia 2Lupin adquiere Biocom en Rusia 3ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 3ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 4Farlie Turner's Consumer Group Completes Sale of Insight Beverages to Kerry 2
... MISSISSAUGA, Ontario, Nov. 18, 2010 Valeant Pharmaceuticals International, ... (the "Company") announced today that Valeant Pharmaceuticals International ... its previously announced offering of senior unsecured notes ... Notes due 2018 (the "Notes"). The $1 billion ...
... Forte Research Systems, makers of OnCore® , the ... organizations and cancer centers in the United States, unveiled ... on Demand , cloud-based clinical research management solution. The ... the clinical trials management system built exclusively for investigational ...
Cached Medicine Technology:Valeant Announces Pricing of Senior Notes 2Valeant Announces Pricing of Senior Notes 3Forte Research Systems Unveils the Allegro™ Research on Demand Cloud-Based Product Line 2
(Date:7/3/2015)... ... July 03, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at ... that he says will reveal biblical truth and expose popular lies regarding proper relationships ... Say Don’t Have Sex”, immediately goes into the core of the subject by explaining ...
(Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... The Celebrity ... or cocktail dresses similar to those of celebrities will have the opportunity to get ... at checkout. This ensures that people do not have to use coupon codes or ...
(Date:7/2/2015)... ... ... sweetFrog Enterprises, LLC. is pleased to announce the opening of its newest location in Dallas, ... The premium frozen yogurt chain was listed as #22 on the Inc. 500 list of ... at Bachman Lake, is located at:, 3701 W. Northwest Highway, STE 430, Dallas, TX 75220 ...
(Date:7/2/2015)... ... ... Following the recent report by JAMA Internal Medicine published on June ... Becic emphatically declared a war on obesity in the United States. , "Obesity is ... understand the magnitude of this discovery. For that reason, I am declaring, along with ...
(Date:7/2/2015)... ... July 02, 2015 , ... When ... project at the University of Minnesota, they knew it would save the university ... be an award-winning choice: the total energy savings after installation was an impressive ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2Health News:Celebrity Fashion Summer Party Dresses on sale at TheCelebrityDresses.com 2Health News:sweetFrog Opens 18th Location in the Lone Star State 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 4Health News:Kenall’s TekDek™ Helps University Achieve Award-Winning Energy Savings in Parking Structure Lighting Retrofit 2
... mortality for hospitalized patients, study found , , TUESDAY, Oct. ... hospitalized for pneumonia was one-third lower for those taking ... a Danish study found. , While the findings are ... doctors can prescribe statins as infection fighters, experts said. ...
... Intentional Interference with ... Prospective Business Advantage, CAMBRIDGE, Mass., Oct. ... it had filed an action for injunctive,relief and damages against ... Hemopure, hemoglobin glutamer-250,(bovine), Biopure,s oxygen therapeutic product for human use. ...
... ... Cost Reduction Efforts Continue to Generate Results ... Step for Visian Toric ICL Application to ... FDA, MONROVIA, Calif., Oct. 28 STAAR ...
... disease rises as the joint ailment worsens, research shows ... (RA) may increase the risk of gum disease, a ... link between RA and periodontal disease, a condition where ... from the gums, loss of bony support, and possible ...
... 28 Blue Mountain Quality,Resources, Inc. announced ... Regulatory Asset Manager(R) to satisfy their immediate ... their enterprise-wide,SAP(R) implementation., "Alexion is committed ... in,its manufacturing facilities and other operations," explains ...
... 28 NASA satellite data can,improve forecasts of ... that can,benefit public health managers. Scientists announced the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081007/38461LOGO ), Led by ... Mexico in,Albuquerque, and William Sprigg of the University ...
Cached Medicine News:Health News:Statins Reduced Death Risk From Pneumonia 2Health News:Statins Reduced Death Risk From Pneumonia 3Health News:Biopure Sues National Institutes of Health Official 2Health News:Biopure Sues National Institutes of Health Official 3Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 2Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 3Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 4Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 5Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 6Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 7Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 8Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 9Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 10Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 11Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 12Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 13Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 14Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 15Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 16Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 17Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 18Health News:Rheumatoid Arthritis May Harm Gums 2Health News:Alexion Pharmaceuticals Chooses Blue Mountain Regulatory Asset Manager(R) for Best-in-class Calibration Management Integrated with SAP(R) 2Health News:NASA-Enhanced Dust Storm Predictions to Aid Health Community 2Health News:NASA-Enhanced Dust Storm Predictions to Aid Health Community 3
... The Bausch & Lomb SoFlex™ ... Lenses are intended to be ... the visual correction of aphakia ... age or older where a ...
... are manufactured using the highest ... CQ UV PMMA material is ... single piece lenses. Unioptic lens ... nonphaco and phaco styles. All ...
Monoflex™ PMMA IOLs for the replacement of the human crystalline lens in the visual correction of aphakia....
... are manufactured using the highest ... CQ UV PMMA material is ... single piece lenses. Unioptic lens ... nonphaco and phaco styles. All ...
Medicine Products: